Compare General Motors Company (GM) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Johnson & Johnson — how do they compare? General Motors Company trades at $82.73 (market cap $72.17B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 8.6× General Motors Company's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Johnson & Johnson for 129 Days on average.
| GM | JNJ | |
|---|---|---|
Market Cap | $72.17B | $618.09B |
Volume | 4,900,304 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $278.43 |
52-Week Low | $55.35 | $186.00 |
Typical Hold Time | 83 Days | 129 Days |
Enterprise Value | $175.15B | $646.37B |
Dividend Yield | 0.88% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 1.56% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong cash flow ($26.9B operating cash flow in 2025) but declining profit margins (1.05% net margin). Recent Q3 2026 sales declined 5.5% as EV demand weakens, though regulatory savings of $20.4B through 2031 provide some offset. Analyst consensus remains bullish with a $102.08 price target representing 24% upside potential.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but long-term value exists through cost savings initiatives and strong cash generation. The stock trades at attractive valuations (P/S 0.42x) with 67% analyst buy ratings, though competitive pressure from Asian automakers and EV transition challenges present significant execution risks for investors.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
